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Abstract
Peritoneal dialysis (PD) is a form of renal replacement therapy
whose repeated use can alter dialytic function through induction
of epithelial–mesenchymal transition (EMT) and fibrosis, eventually
leading to PD discontinuation. The peritoneum from Cav1/ mice
showed increased EMT, thickness, and fibrosis. Exposure of Cav1/
mice to PD fluids further increased peritoneal membrane thick-
ness, altered permeability, and increased the number of FSP-1/
cytokeratin-positive cells invading the sub-mesothelial stroma.
High-throughput quantitative proteomics revealed increased
abundance of collagens, FN, and laminin, as well as proteins
related to TGF-b activity in matrices derived from Cav1/ cells.
Lack of Cav1 was associated with hyperactivation of a MEK-ERK1/2-
Snail-1 pathway that regulated the Smad2-3/Smad1-5-8 balance.
Pharmacological blockade of MEK rescued E-cadherin and ZO-1
inter-cellular junction localization, reduced fibrosis, and restored
peritoneal function in Cav1/ mice. Moreover, treatment of
human PD-patient-derived MCs with drugs increasing Cav1 levels,
as well as ectopic Cav1 expression, induced re-acquisition of
epithelial features. This study demonstrates a pivotal role of Cav1
in the balance of epithelial versus mesenchymal state and suggests
targets for the prevention of fibrosis during PD.
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Introduction
Epithelial–mesenchymal transition (EMT) is a complex and stepwise
process that occurs during embryonic development and tumor
progression, and that has recently been described in chronic inflam-
matory and fibrogenic diseases (Kalluri & Weinberg, 2009; Thiery
et al, 2009; Xu et al, 2009). EMT is characterized by the disruption
of intercellular junctions, replacement of apical–basolateral with
front-to-back polarity, and acquisition of migratory and invasive
phenotypes. During the establishment of EMT, epithelial cells
undergo a complex reprogramming of their cell proteome, in which
proteins commonly expressed by epithelia (E-cadherin, cytokera-
tins) are lost, while cells gain expression of mesenchymal markers
(N-cadherin, vimentin, a-smooth muscle actin (a-SMA), fibroblast
specific protein-1 (FSP-1)). Moreover, cells acquire the ability to
produce extracellular matrix components (ECM) such as fibronectin
(FN) and collagen, as well as metalloproteinases and inflammatory,
fibrogenic, and angiogenic factors. EMT is triggered by a complex
interplay of extracellular signals, including ECM components and
soluble growth factors and cytokines, such as members of the trans-
forming growth factor (TGF)-b, fibroblast growth factor (FGF),
epidermal growth factor (EGF), and hepatocyte growth factor (HGF)
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families (Thiery et al, 2009; Xu et al, 2009; Loureiro et al, 2011).
The molecular mechanisms controlling the initiation and progres-
sion of EMT appear to be multifactorial and cell type specific. The
crucial disruption of intercellular junctions between epithelial cells
in EMT involves a pivotal action of the transcription factors Snail-1,
Zeb, and members of the basic helix-loop-helix (bHLH) family, which
repress E-cadherin expression (Peinado et al, 2007). The expression
of these transcription factors is in turn controlled by a complex
network of signaling molecules, including Smads, integrin-linked
kinase (ILK), phosphatidylinositol 3-kinase (PI3K), mitogen-activated
protein kinases (MAPKs), glycogen synthase kinase (GSK) 3b, and
nuclear factor jB (NF-jB) (Zavadil & Bottinger, 2005; Thiery et al,
2009).
TGF-b-induced signaling pathways are central to many experi-
mental models of EMT. TGF-b signals through a heterotetrameric
complex of two type I and two type II transmembrane serine–
threonine kinase receptors. In response to TGF-b, type II receptor
kinases phosphorylate type I receptors, leading to activation of
cellular responses (Xu et al, 2009). Activated type I receptors
directly activate Smad2 and Smad3 through C-terminal phosphory-
lation. Phosphorylated Smad2 and Smad3 then form trimers with
Smad4, and translocate to the nucleus, where they associate and
cooperate with DNA-binding transcription factors to regulate target
gene transcription. In addition to this classical signaling pathway,
TGF-b receptors can also elicit signaling responses through impor-
tant effector pathways more known for their activation by tyrosine
kinase receptors, such as MAP kinases, Rho GTPases, and PI3K
(Xu et al, 2009).
A particular form of EMT occurs in peritoneal mesothelial cells
(MCs) subjected to repeated inflammatory stimulus, such as those
occurring during peritoneal dialysis (PD). PD is an alternative to
hemodialysis for the treatment of end-stage renal disease (Grassmann
et al, 2005). Currently, PD accounts for more than 10% of all forms
of renal replacement therapy worldwide (Grassmann et al, 2005).
During PD, the peritoneal membrane (PM) acts as a permeable
barrier across which ultrafiltration and diffusion take place (Aroeira
et al, 2007). Continual exposure to hyperosmotic, hyperglycemic
and acidic dialysis solutions, as well as episodes of peritonitis and
hemoperitoneum, can cause acute and chronic inflammation and
injury to the PM, which undergoes progressive fibrosis, angiogenesis,
and vasculopathy, eventually leading to discontinuation of PD.
Among the wide array of extracellular factors implicated in this
process, TGF-b proteins play a major role (Margetts et al, 2005;
Loureiro et al, 2011). The PM undergoes EMT during PD (Yanez-Mo
et al, 2003), and a variety of molecular mechanisms have been
shown to play a role in the regulation of MC plasticity. Signals
transduced via TAK1-NF-jB and an ERK1/2-NF-jB-Snail-1 axis
control downregulation of E-cadherin and the induction of a
mesenchymal state. Conversely, p38 MAPK promotes the mainte-
nance of E-cadherin levels and the epithelial state (Strippoli et al,
2008, 2010, 2012).
Here, we investigated the possible role played by caveolin-1
(Cav1) during EMT. Caveolins are the main structural components
of caveolae, 60- to 80-nm-diameter flask-shaped plasma membrane
invaginations implicated in viral entry, vesicle transport, lipid
metabolism, cell signaling, mechanosensing, and mechanotransduc-
tion (Chidlow & Sessa, 2010; Hansen & Nichols, 2010; Parton & del
Pozo, 2013). Cav1 is widely expressed, and genetic loss of Cav1 in
mice results in almost complete loss of caveolae in vivo, associated
with altered lipid metabolism, pulmonary hypertension and fibrosis,
nitric oxide (NO) dysfunction, and cardiac abnormalities (Drab
et al, 2001; Razani et al, 2001a). We recently reported that stromally
expressed Cav1 promotes biomechanical remodeling of the tumor
microenvironment, thus fostering tumor cell local invasion and
distant metastasis [23]. Here, we demonstrate that absence of Cav1
in mice leads to increased EMT and fibrosis in the peritoneal
membrane (PM), both in basal conditions and upon exposure to
PD fluids. Pharmacological inhibition of the MEK-ERK1/2-Snail-1
pathway, which is hyperactivated in the absence of Cav1, rescued
EMT fibrosis in wild-type (WT) and in Cav1/ mice. Moreover,
endothelial cells (EC), which form part of the PM and share a
mesodermal origin with MCs, acquired mesenchymal-like features
in the absence of Cav1, and overexpression of Cav1 in MCs from
patients undergoing PD promoted a reverse EMT (mesenchymal-to-
epithelial transition; MET). Our results describe a crucial role of
Cav1 in the cellular changes leading to EMT and fibrosis and indi-
cate the therapeutical potential of MEK pharmacological inhibition
for the treatment of PM dysfunction during PD.
Figure 1. Absence of Cav1 promotes EMT-related changes.
A Western blots (WB) showing the expression of E-cadherin, a-SMA, and Cav1 in total lysates of HPMCs not treated (NT) or treated with different doses of TGF-b1 for
24 h. Tubulin was detected as a loading control.
B Top: Photomicrographs of confluent monolayers of HPMCs transfected with either control or Cav1-targeting siRNAs. Scale bar: 100 lm. For quantification of elliptical
factor, see Supplementary Fig S1A. Bottom: Confocal immunofluorescence (IF) of HPMCs treated as above. Cells were fixed, permeabilized, and stained with a
monoclonal antibody against E-cadherin. The IF shown is representative of three independent experiments. Scale bar: 15 lm.
C WB showing the expression of E-cadherin and Cav1 in whole-cell lysates of HPMCs transfected with control (scrambled) or Cav1-targeting siRNAs and then left
untreated (NT) or stimulated for 24 h with TGF-b1 (1 ng/ml; T).
D Western blots showing the expression of vimentin and Cav1 in whole-cell lysates of HPMCs infected with control or Cav1-targeting shRNA lentivirus.
E Western blots showing the expression of E-cadherin, vimentin, a-SMA, and Cav1 in whole-cell lysates of MCs from WT and Cav1/ mice not treated (NT) or treated
with 2 ng/ml TGF-b1 for 48 h (T).
F Differential mRNA expression of a-SMA, type I collagen, and fibronectin (FN) in MCs from WT and Cav1/ mice. Quantitative RT–PCR was performed on total RNA.
Histone H3 mRNA levels were used for normalization. Bars represent means  SEM of duplicate determinations in four independent experiments. *P = 0.02, and
**P = 0.0079 for Cav1/ with respect to WT samples.
G Confocal IF of MCs from WT (top) and Cav1/ mice (bottom). Cells were fixed and stained with a polyclonal antibody against fibronectin (green) and a monoclonal
antibody against a-SMA (red). Nuclei were stained with Hoechst 33342 (blue). The IF shown is representative of three independent experiments. Scale bar: 50 lm.
Data information: In (A, C–E), numbers above panels are ratios of the specific and the tubulin band intensities and data are representative of three independent
experiments
Source data are available online for this figure.
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Results
Cav1 absence promotes an EMT phenotype
Acute and chronic inflammatory events linked to PD induce EMT
and peritoneal membrane fibrosis (Yanez-Mo et al, 2003), in a
process largely dependent on TGF-b1 production (Margetts et al,
2005). TGF-b1 stimulation markedly reduced Cav1 levels in human
primary MCs (HPMCs) in a dose-dependent manner (Fig 1A), and
this was paralleled by reduced expression of the epithelial marker
E-cadherin and induction of the mesenchymal marker a-SMA.
To test the potential involvement of Cav1 in EMT, we first
silenced Cav1 expression in HPMCs. Cav1 silencing led to the
loss of the typical HPMC cobblestone cell architecture and the
acquisition of the characteristic EMT spindle shape (Fig 1B, top, for
quantification see Supplementary Fig S1A). Moreover, Cav1 knock-
down led to reduction of E-cadherin protein expression and also to
its disappearance from cell junctions (Fig 1B, bottom). E-cadherin
downregulation paralleled relevant changes in distribution of
proteins expressed in cell junctions, such as a- b- c-catenin and
occludin (Supplementary Fig S1B–E).
On the other hand, the expression of vimentin, a mesenchymal
marker, was increased (Fig 1D and E). A similar downregulation of
epithelial and induction of mesenchymal markers was detected in ex
vivo cultured MCs from Cav1/ mice (Fig 1E). Transcript analysis
of Cav1/ MCs revealed increased expression relative to wild-type
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Figure 2. Morphological features of PM in Cav1/ mice recapitulate ongoing EMT.
A Microscopy analysis of parietal peritoneum from WT (left) and Cav1/ mice (right). Sections were stained with Masson’s trichrome. Magnification: 200×. *P = 0.016
compared with sections from WT mice. Scale bar: 50 lm.
B Immunofluorescence (IF) analysis of parietal peritoneal tissue sections from WT (left) and Cav1/ mice (right). The sections were stained for pan-cytokeratin (green)
with Hoechst counterstaining. Scale bar: 50 lm.
C Confocal IF of parietal peritoneal sections from WT and Cav1/ mice. The peritoneal membranes were whole-mount-stained with anti-JAM-A monoclonal antibody.
Scale bar: 30 lm.
Data information: Images are representative of the analysis of five mice per group.
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(WT) cells of a-SMA and the ECM proteins FN and type I collagen
(Fig 1F), and increased expression of FN and a-SMA was confirmed
by confocal immunocytochemistry (Fig 1G). The parietal perito-
neum of Cav1/ mice showed a significant thickening of the sub-
mesothelial space and deposition of ECM (Fig 2A). High-throughput
quantitative proteomics analysis of extracellular matrices derived
from WT and Cav1/ murine embryonic fibroblasts (MEFs)
revealed an increase in abundance of ECM proteins such as colla-
gens, FN, and laminin in matrices from Cav1/ MEFs (Fig 3).
Immunohistochemical analysis showed that the MC monolayer
is conserved in the peritoneum of Cav1/ mice (Fig 2B).
However, cytokeratin-positive cells (true MCs) in these sections
had loose intercellular connections and showed a tendency to
invade the sub-mesothelial stroma (see arrows). Whole-mount
staining of the peritoneal membrane showed that MCs from
Cav1/ mice have an elongated, spindlelike shape, with punc-
tate staining for JAM-A, a marker of cellular tight junctions
(Fig 2C).
MEK-ERK1/2-Snail-1 hyperactivation participates in EMT
induction by Cav1/ MCs
Cav1 deficiency is linked to increased activity of AKT and ERK1/2
in heart and lung (Wang et al, 2006; Murata et al, 2007). We found
that ERK1/2 is basally hyperactivated in MCs from Cav1/ mice
and in Cav1-silenced HPMCs (Fig 4A and B), and basal and TGF-b1-
stimulated ERK1/2 activity was strongly inhibited by the specific
MEK inhibitor CI-1040 (Sebolt-Leopold et al, 1999) (Fig 4A).
Moreover, CI-1040 increased E-cadherin transcript and protein
expression in Cav1/ MCs (Fig 4A and C).
Collagens & Collagen-associated proteins
xq-X
Q61245|COBA1_MOUSE Collagen alpha-1(XI) chain GN=Col11a1 -1.299
P28301|LYOX_MOUSE Protein-lysine 6-oxidase  GN=Lox -1.053
Q00780|CO8A1_MOUSE Collagen alpha-1(VIII) chain GN=Col8a1 -0.942
Q60847|COCA1_MOUSE Collagen alpha-1(XII) chain GN=Col12a1 -0.928
E9PWQ3|E9PWQ3_MOUSE Uncharacterized protein GN=Col6a3 -0.874
Q01149|CO1A2_MOUSE Collagen alpha-2(I) chain GN=Col1a2 -0.869
P11087|CO1A1_MOUSE Collagen alpha-1(I) chain GN=Col1a1 -0.641
O88207|CO5A1_MOUSE Collagen alpha-1(V) chain GN=Col5a1 -0.573
Q02788|CO6A2_MOUSE Collagen alpha-2(VI) chain  GN=Col6a2 -0.379
Q04857|CO6A1_MOUSE Collagen alpha-1(VI) chain  GN=Col6a1 -0.335
Q8K4Q8|COL12_MOUSE Collecn-12  GN=Colec12 -0.296
Q60716|P4HA2_MOUSE Prolyl 4-hydroxylase subunit alpha-2  GN=P4ha2 -0.294
Q99K41|EMIL1_MOUSE EMILIN-1  GN=Emilin1 -0.277
Q9Z0I9|Q9Z0I9_MOUSE Collagen alpha3(VI) (Fragment)  GN=Col6a3 -0.243
Q61398|PCOC1_MOUSE Procollagen C-endopepdase enhancer 1  GN=Pcolce -0.208
Q63870|CO7A1_MOUSE Collagen alpha-1(VII) chain GN=Col7a1 -0.184
Q07563|COHA1_MOUSE Collagen alpha-1(XVII) chain GN=Col17a1 -0.025
P28481|CO2A1_MOUSE Collagen alpha-1(II) chain GN=Col2a1 0.0266
P02463|CO4A1_MOUSE Collagen alpha-1(IV) chain GN=Col4a1 0.2858
P28654|PGS2_MOUSE Decorin GN=Dcn 0.4392
B1AVK5|B1AVK5_MOUSE Procollagen type IV alpha 6  GN=Col4a6 0.6438
Other ECM  proteins
xq-X
P50608|FMOD_MOUSE Fibromodulin GN=Fmod -2.466
O70326|GREM1_MOUSE Gremlin-1  GN=Grem1 -1.848
P19137|LAMA1_MOUSE Laminin subunit alpha-1  GN=Lama1 -1.328
Q62009|POSTN_MOUSE Periosn GN=Postn -1.098
Q6NWW9|FND3B_MOUSE Fibronecn type III domain-containing protein 3B  GN=Fndc3b -0.959
Q9R0E2|PLOD1_MOUSE Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1  GN=Plod1 -0.933
Q61554|FBN1_MOUSE Fibrillin-1  GN=Fbn1 -0.8
O08999|LTBP2_MOUSE Latent-transforming growth factor beta-binding protein 2 GN=Ltbp2 -0.755
P07214|SPRC_MOUSE SPARC  GN=Sparc -0.689
O08573|LEG9_MOUSE Galecn-9  GN=Lgals9 -0.686
O35598|ADA10_MOUSE Disintegrin and metalloproteinase domain-cont. protein 10  GN=Adam10 -0.625
P97298|PEDF_MOUSE Pigment epithelium-derived factor  GN=Serpinf1 -0.598
O35646|CAN6_MOUSE Calpain-6  GN=Capn6 -0.551
P19324|SERPH_MOUSE Serpin H1  GN=Serpinh1 -0.512
P35441|TSP1_MOUSE Thrombospondin-1  GN=Thbs1 -0.509
Q9Z0F8|ADA17_MOUSE Disintegrin and metalloproteinase domain-cont. protein 17  GN=Adam17 -0.29
A2AQ53|A2AQ53_MOUSE Fibrillin 1  GN=Fbn1 -0.143
P23188|FURIN_MOUSE Furin GN=Furin 0.0546
Q61555|FBN2_MOUSE Fibrillin-2  GN=Fbn2 0.482
P16110|LEG3_MOUSE Galecn-3  GN=Lgals3 0.5225
Q80YX1|TENA_MOUSE Tenascin GN=Tnc 0.6804
P16045|LEG1_MOUSE Galecn-1  GN=Lgals1 1.1054
Figure 3. High-throughput quantitative proteomics analysis of proteins from WT and Cav1/ cells.
The points represent the distribution of corrected log2 ratios (WT/KO) (Xq-X) of protein quantifications according to their statistical weight (Wq, a parameter that measures the
accuracy of protein quantifications, according to the WSPP model (Navarro et al, 2014)). The corrected log2 ratios of collagens and associated proteins, and of other
ECM-related proteins, are listed in the right table. Negative values represent an increase in KO cells, and the colors in the table are graded from green (increase) to red
(decrease).
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The ERK pathway is a major inducer of Snail-1 family proteins,
which directly repress E-cadherin expression (Cano et al, 2000;
Strippoli et al, 2008). Hyperactivation of ERK1/2 in Cav1/ MCs
could thus contribute to the observed low E-cadherin expression by
increasing expression of Snail-1 proteins. MCs from Cav1/ mice
express more Snail-1 transcript and protein than WT MCs, both
basally and upon TGF-b1 stimulation (Fig 4D and E). Confocal
immunofluorescence showed that Snail-1 expression was mainly
nuclear, and paralleled higher levels of phospho-MEK in Cav1/
MCs (Fig 4F). CI-1040 reduced the expression of Snail-1 transcript
and protein in WT and Cav1/ MCs, accompanied by a drop in the
level of phospho-MEK (Fig 4D–F and Supplementary Fig S2A).
Nuclear localization of SMAD2/3 was higher in Cav1/ MCs than
inWT (Fig 4G). Interestingly, CI-1040 significantly reduced SMAD2-3
nuclear staining. To further explore the effect of MEK-ERK
signaling on SMAD nuclear localization and activity, we transfected
the untransformed mesothelial cell line MeT-5A with a luciferase
reporter construct containing multiple SMAD3 binding sites or with
a reporter containing the id1 promoter, which specifically binds
SMAD1-5. CI-1040 reduced TGF-b-stimulated SMAD3-driven lucif-
erase expression and C-terminal phosphorylation (linked to tran-
scriptional activity), whereas it had the opposite effect on basal
and stimulated activity of SMAD1-5 (Supplementary Fig S2B–D).
Interestingly, Cav1 knockdown increased expression of FN and
PAI-1, controlled by SMAD3, and of Snail-1. In the reverse experi-
ment, expression of these proteins was reduced upon overexpres-
sion of lentivirally encoded Cav1 (Supplementary Fig S2E).
These findings are in good agreement with the quantitative prote-
omics analysis of MEF-derived extracellular matrices, which showed
an increase in abundance of proteins directly or indirectly related to
TGF-b activity such as fibromodulin, gremlin-1, LTBP2 (latent-
transforming growth factor beta-binding protein 2), SPARC, metallo-
proteases, serpins, and thrombospondin-1 in matrices from Cav1/
mice (Fig 3). These results show that Cav1 deficiency in MCs
increases Snail-1 expression and SMAD3 nuclear translocation, and
suggest that MEK, in addition to controlling the ERK-Snail-1 path-
way, also affects SMAD function, enhancing SMAD2-3 activity while
reducing that of SMAD1-5.
Acquisition of a spindlelike cell morphology and increased
permeability by Cav1/ MCs depend on the
MEK-ERK1/2 pathway
MCs from Cav1/ mice have a spindlelike morphology compared
with the typical cobblestone epithelial appearance of WT MC
cultures (Fig 5A, for a quantification see Supplementary Fig S3A).
Moreover, MCs from Cav1/ mice show flattened morphology with
reduced cell height, suggesting acquisition of a mesenchymal-like
phenotype (Fig 5B) (Mukhina et al, 2004). Treatment of Cav1/
MCs with CI-1040 induced reversion to an epithelial-like phenotype
in MCs from mice. We reproduced this experiment in Cav1 silenced
HPMCs. Cav1 knockdown induced disappearance of E-cadherin and
ZO-1 from membrane junctions, whose levels were significantly
restored upon treatment with CI-1040 (Fig 5C, for a quantification
see Supplementary Fig S3B).
The reduced expression and altered localization of E-cadherin
and other proteins located at cell junctions in the absence of Cav1
imply functional alterations of cell permeability, an important func-
tion of MCs during peritoneal dialysis. This was confirmed by ex
vivo analysis of dextran leakage, which revealed a markedly higher
permeability in Cav1/ MC cultures that was reverted by treatment
with CI-1040 (Fig 5D).
Enhanced migration and invasion by Cav1/ MCs is
dependent on MEK-ERK1-2
The acquisition of migratory and invasive capacities is typical of
cells undergoing EMT (Thiery et al, 2009). To investigate the effect
of Cav1 on these properties, we analyzed MC migration through
transwell filters. MCs from Cav1/ mice migrated more efficiently
than WT cells through uncoated filters (Fig 6A), and a more
pronounced effect was obtained in assays of invasiveness across
filters coated with type I collagen (Fig 6B), indicating that MCs lack-
ing Cav1 acquire the capacity to degrade ECM, a characteristic of
cells that have undergone EMT (Thiery et al, 2009). In both assays,
the migratory/invasive advantage of Cav1/ MCs was abolished by
CI-1040.
Figure 4. ERK/Snail-1 hyperactivation in Cav1-deficient mouse and human MCs.
A WB for E-cadherin, phospho-ERK1/2, and Cav1 in total cell lysates of MCs. Cells were treated with vehicle (DMSO, D) or CI-1040 (CI, 2 lM) for 24 h. Tubulin was
detected as a loading control. Data are representative of three independent experiments.
B WB for phospho-ERK1/2 and Cav1 in total cell lysates of HPMCs transfected with control or Cav1-targeting siRNAs and then stimulated as indicated for 30 min
with TGF-b1 (T, 1 ng/ml). Scrambled: cells transfected with control siRNA. Tubulin was detected as a loading control. Data are representative of three independent
experiments.
C Effect of pharmacologic inhibition of MEK on E-cadherin mRNA expression in MCs from WT or Cav1/ mice. Cells were treated with 2 lM CI-1040 or DMSO for
24 h, and mRNA was amplified from total RNA by quantitative RT–PCR; histone H3 mRNA expression was used for normalization. **P = 0.0015; *P = 0.02.
D Effect of pharmacologic inhibition of MEK on Snail-1 mRNA expression in MCs from WT or Cav1/ mice. Cells were pretreated with 2 lM CI-1040 (CI) or DMSO
(D) for 1 h and stimulated with TGF-b1 (2 ng/ml) for 12 h. Normalization as in (C). Bars represent means  SEM of duplicate determinations in five independent
experiments. **P = 0.0037; *P = 0.04.
E Effect of pharmacologic inhibition of MEK on Snail-1 protein expression in MCs from WT or Cav1/ mice. Cells were pretreated with 2 lM CI-1040 or DMSO for
1 h and then stimulated as indicated with TGF-b1 (T, 2 ng/ml) for 3 or 12 h. Tubulin was detected as a loading control. Data are representative of three
independent experiments.
F, G Top: Confocal IF of MCs from WT and Cav1/ mice. (F) Cells were fixed and immunostained for phospho-MEK1 and Snail-1. Nuclei were stained with Hoechst
33342. Scale bar: 15 lm. (G) Cells were pretreated with 2 lM CI-1040 or DMSO for 1 h and then stimulated with TGF-b1 (2 ng/ml) for 12 h. Cells were fixed and
immunostained for SMAD2-3 (red). Nuclei were stained with Hoechst 33342 (blue). Scale bar: 15 lm. Bottom: The histograms show mean fluorescence intensities of
nuclear staining quantified using the software LAS-AS from Leica. Bars represent s.e.m. A total of at least 150 cells were analyzed per condition from three different
experiments. Data are representative of three independent experiments. ***P < 0.001 and ***P < 0.001 for Snail-1(F, left); ***P = 0.0008 and ***P < 0.001 for
phospho-MEK1 (F, right); and ***P < 0.001 and ***P < 0.001 for SMAD2-3 (G) nuclear staining.
Source data are available online for this figure.
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Cav1/ MCs also showed a greater invasive capacity than WT
cells in a 3-dimensional invasion assay on matrigel matrices
(Fig 6C). In this assay, bundles of cytokeratin-positive (green)
Cav1/ cells were detected emerging from the top of the gel, ruling
out the possibility that the invasiveness of Cav1/ cells was due to
contamination of the MC preparation with fibroblasts. As with the
other assays, invasion through matrigel by Cav1/ MCs was
blocked by CI-1040 (Fig 6D and E).
Endothelium of Cav1-deficient mice has a
mesenchyme-like phenotype
Mouse lung endothelial cells (MLEC) share a mesodermal origin
with MCs and have similar morphological and functional properties;
moreover, both cell types express abundant Cav1, which is
reduced by treatment with TGF-b1 (Igarashi et al, 2009). Like
MCs, MLECs undergo a transition to a mesenchymal phenotype
(EndMT) upon exposure to pro-fibrotic and inflammatory stimuli
or shear stress (Zeisberg et al, 2007; Egorova et al, 2011; Medici &
Kalluri, 2012). EndMT induction has been directly linked to Snail-1
expression (Kokudo et al, 2008), and we found that immortalized
Cav1/ MLECs upregulated Snail-1 expression, an effect reversed
upon Cav1 reconstitution (Fig 7A). Consistent with induction of
EndMT, primary Cav1/ MLECs expressed higher levels of
a-SMA, type I collagen, and FN than cells from WT mice (Fig 7B
and C).
In addition, and resembling the results obtained with MCs,
MLECs from Cav1/ mice had a spindlelike morphology in ex
vivo culture (Fig 7D) and acquired a fibroblastoid shape when
treated with TGF-b1 in combination with IL-1b, a costimulation
known to induce full EMT in HPMCs (Yanez-Mo et al, 2003;
Strippoli et al, 2008). Moreover, a polarized endothelial-cell
morphology was also evident in whole-mount staining of Cav1/
aorta (Fig 7E). These morphological changes were accompanied by
increased endothelial permeability (estimated from vessel dye leak-
age), both in steady state and in response to aptene-induced
inflammation (Fig 7F).
CI-1040 prevents fibrosis, EMT, and altered peritoneal membrane
function in Cav1/ mice undergoing PD
To study the role of Cav1 in the peritoneal EMT and fibrosis that
occurs in patients undergoing PD, we used a mouse model of PD
(Aroeira et al, 2008), in which mice are instilled daily with
glucose-based PD fluids over a three-week period. Masson’s
trichrome staining of the parietal peritoneum of control animals
revealed a thicker submesothelial space in Cav1/ mice, and this
thickening was significantly increased by exposure to PD fluids
(Fig 8A and B). As expected, ERK1/2 activation was higher in
peritoneal tissue from Cav1/ mice exposed to PD fluids with
respect to WT tissue (Supplementary Fig S4A). Similar to TGF-b1
stimulation (Fig 1A), exposure to PD fluid markedly reduced Cav1
levels in ex vivo cultured MCs from WT mice (Supplementary
Fig S4B).
The induction of EMT in response to PD fluids was monitored by
immunofluorescence analysis of parietal peritoneal sections for
cytokeratin (MC marker) and FSP-1 (used as a marker of myofibro-
blasts and EMT conversion). Exposure of WT and Cav1/ mice to
PD fluids caused discontinuity and loss of the cytokeratin-positive
MC monolayer (Fig 8C, top). However, sections from Cav1/ mice
contained higher numbers of cytokeratin-FSP-1 double-positive MCs
invading the submesothelial stroma (Fig 8C and D) and of CD31-
positive cells in the sub-mesothelial space, indicating increased
angiogenesis in Cav1/ mice (Fig 8E, see arrow).
Treatment with CI-1040 during the period of PD fluid exposure
abolished ERK1/2 phosphorylation in WT and Cav1/ mice
(Supplementary Fig S4C), and markedly reduced peritoneal thick-
ening and EMT (Fig 8A–D). Moreover, CI-1040 blocked the increase
in CD31-positive cells in the peritoneum of PD-fluid-treated Cav1/
mice (Fig 8E). The cell-division Ki67 marker was not significantly
increased in Cav1/ peritoneum upon exposure to PD fluid, indi-
cating that the increased peritoneal fibrosis and angiogenesis in
these animals were not directly related to increased cell proliferation
during the analysis period (Supplementary Fig S5).
The functional impact of the observed morphological changes
in the peritoneum was assessed by a peritoneal equilibration test
on the last day of treatment. Mice from all groups were injected
with 1.5 ml PD solution, and total peritoneal volumes were
recovered 30 min later. The volumes recovered from PD-fluid-
exposed Cav1/ mice were significantly lower than those recov-
ered from WT mice, indicating increased permeability in the peri-
toneum of Cav1/ mice (Fig 8F). The permeability alterations in
Cav1/ mice were significantly inhibited by co-treatment with
CI-1040.
These results demonstrate a major role of MEK/ERK1/2 signaling
in the events leading to EMT and fibrosis during PD, and identify
Cav1 as an important regulator of these events.
Ectopic expression of Cav1 in MCs from PD patients reverses EMT
HPMCs isolated from the effluent of patients undergoing PD are a
useful model for the analysis of the changes occurring in the
Figure 5. Morphological, biochemical, and functional features in the absence of Cav1 depend on ERK1/2 pathway.
A Confocal IF of phalloidin and cytokeratin expression and localization in MCs from WT (left) and Cav1/ mice (right). Cells were treated with 2 lM CI-1040
or DMSO for 48 h. Fixed and permeabilized cells were stained with phalloidin (F-actin) and immunostained for cytokeratin. Cell nuclei were stained with
Hoechst 33342. Scale bar: 25 lm. Images show the results of a representative independent experiment of three performed. For quantification of elliptical
factor, see Supplementary Fig S3A.
B Left: Representative X–Z images are shown from the experiment described in (A). Arrows indicate the maximal apical dimensions used to calculate cell height. Right:
quantification of cell height in the experiment described above. Scale bar: 10 lm. ***P < 0.001.
C Confocal IF of E-cadherin (top), actin, and ZO-1 expression (bottom) in HPMCs transfected with control or Cav1-targeting siRNAs and then treated for 48 h with
DMSO or with 2 lM CI-1040. Nuclei were stained in the bottom images with Hoechst 33342 (blue). Images show the results of a representative independent
experiment of three performed. For quantification of intensity, see Supplementary Fig S3B. Scale bar: 15 lm.
D Permeability of WT and Cav1/ MC monolayers. Cells grown on filter inserts were pretreated with DMSO or CI-1040 (2 lM) for 1 h, and the permeability to
fluorescent dextran was monitored over time (40-min values shown). The image shows the result of 8 experiments performed. Scale bar: 15 lm. *P = 0.027.
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peritoneal HPMC monolayer in vivo in patients undergoing EMT
(Del Peso et al, 2008). Immunostaining of these cells for Cav1
revealed a heterogeneous pattern, with Cav1 expression inversely
correlating with the expression of a-SMA (Fig 9A). To evaluate the
role of Cav1 in the EMT status of these cells, we overexpressed
lentivirally encoded Cav1, which resulted in rescue of E-cadherin
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Figure 6. Migratory and invasive phenotype of Cav1/ MCs depends on ERK1/2 pathway.
A Effect of MEK inhibition on MC migration through transwell filters. MCs from WT and Cav1/ mice were pretreated with DMSO or CI-1040 (2 lM) for 24 h and
allowed to migrate for 24 h through transwell filters. Migrating cells were fixed and nuclei-counted in ten fields per sample using a fluorescence microscope (40×
magnification). Each experiment was performed in duplicate, and 5 experiments were performed. *P = 0.03.
B Effect of MEK inhibition on MC invasion through type I collagen-coated transwell filters. Cells were treated as above. *P = 0.016 for WT versus Cav1/ MCs and
*P = 0.010 for DMSO- versus CI-1040-treated Cav1/ MCs.
C Effect of MEK inhibition on three-dimensional invasion by WT and Cav1/ MCs. MCs were pretreated (24 h) with DMSO or CI-1040 (2 lM) and then overlaid with a
matrigel+collagen matrix. Invasion was monitored over 24 h. Three-dimensional invasion was enhanced by adding 10% FCS to the well. Cells were fixed and stained
with anti-cytokeratin (green), phalloidin (red), and Hoechst 33342 (cell nuclei; blue). Left: xz maximal projection; right: xy acquisition at the top of the well (Cav1/
MCs). Scale bar: 100 lm. Each experiment was performed in duplicate, and 5 experiments were performed.
D Full 3D invasion experiment. Hoechst-stained nuclei are shown in yellow; phalloidin in blue. Scale bar: 50 lm.
E Quantification of MC invasion of 3D matrix. Each experiment was carried out in triplicate, and three experiments were performed. ***P < 0.001 for WT versus Cav1/
MCs and ***P < 0.001 for DMSO- versus CI-1040-treated Cav/ MCs.
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expression and a decrease in a-SMA levels (Fig 9B). Consistent with
these findings, E-cadherin expression in patient-derived HPMCs was
further reduced by Cav1 knockdown, and this effect was partially
rescued by treatment with CI-1040 (Fig 9C). Furthermore, Cav1
knockdown increased vimentin levels, which were again reduced
upon ectopic Cav1 expression (Fig 9D). The direct correlation
between Cav1 and E-cadherin expression and the inverse correlation
between Cav1 and Snail-1 expression were confirmed by RT–PCR
under the same experimental settings (Fig 9E and F). Cav1 knock-
down also significantly increased the invasive capacity of patient-
derived HPMCs on collagen-coated transwell filters, whereas ectopic
Cav1 expression in the same cells had the opposite effect (Fig 9G).
Interestingly, exposure of HPMCs to dexamethasone or tamoxifen,
two drugs endowed with anti-inflammatory or anti-fibrotic activity,
respectively, led to increased Cav1 levels, and a concomitant increase
in E-cadherin levels and a reduction in those of a-SMA and vimentin
(Supplementary Fig S6A–C)(Jang et al, 2013; Loureiro et al, 2013).
Discussion
While Cav1 has been widely studied for its role in endocytosis and
cell signaling organization, its possible implication in EMT-related
fibrosis has been scarcely addressed (Gvaramia et al, 2013). The
results presented here establish a pivotal role for Cav1 in the EMT
associated with PD-induced PM deterioration and demonstrate the
effectiveness of inhibiting the MEK-ERK1/2 pathway in blocking or
reversing these events. Lack of Cav1 in human and mouse MCs is
linked to acquisition of a pre-EMT phenotype characterized by loss
of the ‘cobblestone’ epithelial morphology, a switch from epithelial
to mesenchymal marker expression, ECM production, and an
enhanced migratory and invasive capacity. Proteomics analysis of
MEF-derived extracellular matrices revealed increased abundance of
ECM proteins and of proteins related to enhanced TGF-b1 activity in
matrices produced by MEFs from Cav1/ mice. These changes
correlate with peritoneal thickening and permeability in Cav1/
mice and with activation of ERK1/2, Snail-1 expression, and
SMAD2-3 nuclear localization, and all pre-EMT phenotypic features
are blocked or reversed by the MEK inhibitor CI-1040.
Similar changes occur in Cav1/ endothelial cells. Moreover,
EMT, angiogenesis, and peritoneal permeability induced by PD fluid
are more severe in Cav1/ mice and are blocked by CI-1040. The
clinical relevance of these findings is confirmed by the ability of
ectopic Cav1 to reverse EMT in MCs from PD patients, whereas
EMT is exacerbated by Cav1 suppression.
The reduced expression or/ and altered localization of intercellu-
lar junction proteins in the absence of Cav1 are consistent with
defective function of the peritoneal membrane as a semi-permeable
barrier during PD. This is supported by the ex vivo assays showing
high permeability of Cav1/ MC monolayers compared with WT
cells. This may be related to the EMT-like state of Cav1/ MCs,
characterized by a loosening of cell junctions. Accordingly, in vivo
permeability assay detected microvascular leakage in Cav1/ mice,
confirming previous studies showing that lack of Cav1 causes
microvascular hyperpermeability due to hyperactivation of endothe-
lial nitric oxide synthase (eNOS) (Schubert et al, 2002; Murata et al,
2007). Other studies reported enhanced transvascular protein trans-
port in Cav1/ mice, probably reflecting passive filtration across
large pores in a context of increased microvascular pressure (Rosen-
gren et al, 2006; Grande et al, 2009). Our ex vivo results suggest that
MC monolayer permeability is altered per se, in the absence of
elevated microvascular pressure. The increased permeability
observed in the microvasculature of Cav1/ mice may also contrib-
ute to the altered functional properties of the PM during PD, a
hypothesis reinforced by the peritoneal equilibration test performed
on the last day of the treatment of mice with PD fluids; the lower
volumes recovered from the peritoneum of Cav1/ mice suggest a
higher peritoneal permeability in these mice.
Mesothelial and endothelial cells have a common mesodermal
origin and share morphological and functional features. Moreover,
like MC EMT, TGF-b-induced EndMT requires Snail-1 (Kokudo et al,
2008). Our experiments show that Cav1 suppresses a-SMA and
Snail-1 expression in primary and immortalized MLECs, and Cav1/
MLECs and in situ aortic endothelium are spindle-shaped, suggest-
ing EndMT onset. Interestingly, Cav1 has been demonstrated to
regulate the expression of junction-associated proteins in brain
microvascular endothelial cells (Song et al, 2007). Our study is
further supported by the recent observation that Cav1 deficiency
leads to increased a-SMA and Snail-1 expression in mouse pulmo-
nary ECs in vitro (Li et al, 2012). Overall, our results suggest that
Cav1 controls biochemical, morphological and functional parame-
ters linked to EndMT.
There are several possible mechanisms through which Cav1
might regulate the establishment of EMT and fibrosis in the perito-
neal membrane. Cav1, through its scaffolding domain (CSD), inter-
acts with and downregulates serine and tyrosine kinases such as
Src, AKT, and H-Ras, thus controlling cell cycle and regulating gene
expression (Couet et al, 1997; Murata et al, 2007). The lack of direct
evidence for interaction between the CSD and caveolin-binding
motifs (CBM) in Cav1-interacting proteins has challenged the CSD/
CBM hypothesis (Collins et al, 2012); however, understanding of
the effect of Cav1 or CSD on signaling pathways is far from
complete (Parton & Del Pozo, 2013). For some proteins, such as
those belonging to the Ras family of GTPases and to the Src family
of kinases, Cav1 might regulate membrane versus cytoplasmic local-
ization, and thus activity, by controlling associations with liquid-
ordered PM domains (del Pozo et al, 2005; Norambuena &
Schwartz, 2011). A candidate mechanism for Cav1-mediated down-
regulation of MEK1 activity is cooperation with the endogenous
Ras/MAPK inhibitor Dok1 to promote MEK1 localization in the cyto-
sol (Burgermeister et al, 2011). The recent observation that Cav1
may modulate MEK-ERK1/2 signaling pathway through organiza-
tion of Ras microclusters (Ariotti et al, 2014) fits with our results,
emphasizing the role of Cav1 in the regulation MEK-ERK1/2-driven
EMT.
Previous studies of the role of Cav1 in EMT were mostly
conducted in experimental models of cancer. Lu et al (2003)
demonstrated in an in vitro system that chronic EGF treatment of
carcinoma cell lines resulted in transcriptional Cav1 downregula-
tion and induction of Snail-1, correlating with downregulation of
E-cadherin expression and increased invasion of collagen gels. The
inverse relationship between Cav1 and Snail-1 was recently
confirmed in a model of pancreatic cancer, and the same study
also showed the correlation between Cav1 and E-cadherin expres-
sion (Salem et al, 2011). In an ovarian carcinoma setting, ectopic
expression of Cav1 stabilized adherens junctions through inhibition
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of Src-related kinases (Miotti et al, 2005). Snail-1, in addition to
directly targeting E-cadherin expression, downregulates other
proteins associated with cell junctions, such as claudins and occlu-
din, with knock-on effects on the expression of other proteins such
as metalloproteinases, integrins and ECM proteins (Thiery et al,
2009). Snail-1 can alter cell polarity through repression of Crumbs
and can control cell scattering and invasiveness (Haraguchi et al,
2008; Whiteman et al, 2008; Stanisavljevic et al, 2011). In a non-
tumoral setting, Snail-1 overexpression is sufficient to induce renal
fibrosis (Boutet et al, 2006).
Our study emphasizes the central role of MEK-ERK1/2 suppres-
sion in Cav1-mediated regulation of EMT and fibrosis. In agree-
ment with our results, ERK1/2 hyperactivation has been
previously demonstrated in Cav1/ mice and is reduced by Cav1
re-expression (Engelman et al, 1998; Wang et al, 2006). Activated
ERK1/2 in the absence of Cav1 might trigger EMT by targeting
the transcription factor Egr1 to the Snail-1 promoter, thus enhanc-
ing Snail-1 transcriptional activity (Grotegut et al, 2006).
However, Cav1 may also regulate EMT independently of MEK/
ERK1/2 signals. Cav1 dampens SMAD2-3 signaling through an
interaction with TGF-b1 type 1 receptors (Razani et al, 2001b),
and TGF-b1 type 1 and type 2 receptors are internalized in Cav1-
containing vesicles that target them to the degradation pathway
(Di Guglielmo et al, 2003). Cav1 modulates SMAD2 and SMAD3
nuclear accumulation in fibroblasts in an experimental model of
idiopathic pulmonary fibrosis (Wang et al, 2006). Another possi-
bility is that, in addition to a direct effect on SMADs, Cav1 defi-
ciency indirectly modifies TGF-b1-driven SMAD activation through
a MAPK-mediated effect. In our study, MEK inhibition dampened
SMAD3 nuclear translocation while enhancing SMAD1-5-8 signal-
ing. Previous studies demonstrated that ERK phosphorylation of
the SMAD1 polylinker region inhibits SMAD1 nuclear accumula-
tion and transcriptional activity (Kretzschmar et al, 1997). More
recently, ERK activation was shown to increase the half-life of
C-terminal phosphorylation of SMAD2 and SMAD3 and to
increase their transcriptional activity (Hough et al, 2012). This
complex interrelationship of Cav1 with the MEK/ERK and SMAD
pathways in the regulation of mesothelial cell EMT is summarized
in Fig 10. De-repression of MEK-ERK-Snail-1 signaling pathway by
Cav1 deficiency directly promotes E-cadherin downregulation, a
hallmark of EMT. ERK1/2 hyperactivation further unbalances the
SMAD2-3/SMAD1-5 pathways, favoring the pro-fibrotic SMAD2-3
pathway.
The structure of the visceral and parietal peritoneum is similar in
humans, rats, and mice (Nishino et al, 2007), suggesting that exper-
iments in genetically modified mice can provide valuable informa-
tion about the damage associated with clinical PD. Here, we present
what is to our knowledge the first analysis of the effect of PD-fluid
exposure in a genetically modified animal model. Our results
suggest that lack of Cav1 causes a series of changes leading to
increased invasion by trans-differentiated MCs of the sub-mesothelial
stroma, fibrosis, and altered peritoneal permeability. The abnormal
migratory and invasive capacities of Cav1/ MCs were furthermore
confirmed in ex vivo migration and invasion assays.
The detection of an EMT-like phenotype in Cav1-deficient meso-
thelial and endothelial cells indicates that both cell types are likely
to participate in the establishment of peritoneal tissue damage and
functional alteration during PD. TGF-b1 and VEGF produced by
MCs during PD might induce EC proliferation and EndMT (Lai et al,
2000; Aroeira et al, 2005), and the subsequently increased solute
diffusion through leaky EC junctions might contribute to the progres-
sion of tissue fibrosis in the sub-mesothelial stroma.
An important finding of our study is the ability of the MEK
inhibitor CI-1040 to block EMT and fibrosis in mice exposed to PD
fluids. MEK inhibition is an active focus of oncology research, but
less attention has been paid to its role in acute and chronic
inflammation, despite the important role of MEK/ERK1/2 signals in
the induction and resolution of inflammation (Chappell et al, 2011).
Our findings are consistent with others showing that CI-1040
reduces kidney fibrosis and TGF-b1 expression in a mouse model of
chronic allograft nephropathy (Wang et al, 2008). In another study,
CI-1040 reduced IL-1b production and ECM alterations in a mouse
model of arthritis (Thiel et al, 2007). CI-1040 has been replaced
for clinical studies by new MEK inhibitors, due mainly to concerns
about physical properties and bio-availability; however, no concerns
have been raised about this drug’s specificity, and therefore,
information obtained with it provide a foundation for future work
with new and more potent MEK inhibitors (Barrett et al, 2008;
Chappell et al, 2011).
The clinical relevance of our results is further demonstrated by
the experiments HPMCs from the effluent of PD patients. These
cells, having undergone EMT in vivo, present low levels of E-cadh-
erin, high levels of a-SMA, and ERK1/2 activation (Yanez-Mo et al,
2003; Strippoli et al, 2008). Ectopic expression of Cav1 in these
cells increased E-cadherin and reduced a-SMA levels. Rescue of
E-cadherin in post-EMT human cells in vivo could have important
Figure 7. EMT-like status of mouse lung endothelial cells (MLEC) from Cav1/ mice.
A The levels of Snail-1 transcript in WT, Cav1/ or Cav1 reconstituted (Cav1 rec) immortalized MLECs. mRNA was amplified from total RNA by quantitative RT–PCR;
histone H3 mRNA expression was used for normalization. Bars represent means  SEM of duplicate determinations in four independent experiments. **P = 0.003;
*P < 0.033.
B The levels of a-SMA and type I collagen transcripts in WT or Cav1/ MLECs. PCR amplification and normalization as in (A); **P = 0.002. Bars represent
means  SEM of duplicate determinations in four independent experiments.
C Western blot for FN, a-SMA, Snail-1, and Cav1 in total lysates of primary MLECs by WB from WT and Cav1/ mice. Tubulin was detected as a loading control. Data
are representative of three independent experiments.
D Top: Confocal IF of primary MLECs from WT (left) and Cav1/ mice (right). Cells were fixed and stained for CD31 (green) and b-catenin (red). Bottom: Confocal IF of
primary MLECs from WT (left) and Cav1/ mice (right). Cells were stimulated with TGF-b1 (2 ng/ml) in combination with IL-1b (0.5 ng/ml) for 48 h. Cells were fixed
and stained for CD31 (green) and a-SMA (red). Nuclei were stained with Hoechst 33342 (blue). Representative images are shown of one experiment of three
performed. Scale bar: 50 lm. The adherence to ICAM2 coated beads, used for MLEC purification, (see arrows), confirms the endothelial origin of these cells.
E Confocal IF of aorta sections from WT and Cav1/ mice. Aortas were fixed in vivo, sectioned and stained with monoclonal anti-VE-cadherin. Scale bar: 30 lm.
Bottom: quantification of elliptical factor with MetaMorph. ***P < 0.001. Representative images are shown of one experiment of five performed.
F Intravital imaging of paravascular permeability in ears of WT (top) and of Cav1/ mice (bottom) under steady state (left) or inflammatory conditions (right).
TRITC-dextran was used as vascular tracer. The images shown are representative of five independent experiments. Scale bar: 50 lm.
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Figure 8. The MEK inhibitor CI-1040 reverses thickening, fibrosis, and angiogenesis in the parietal peritoneum of Cav1/ mice upon exposure to PD fluid.
WT or Cav1/mice were exposed to peritoneal dialysis (PD) fluid or sham 5 times per week for three weeks with contemporaneous treatment with CI-1040 (200 mg/kg) or
vehicle. Eight mice were analyzed per group.
A Representative hematoxylin and eosin staining of parietal peritoneum sections. Scale bar: 50 lm.
B Quantification of peritoneal membrane thickness. *P = 0.035 for WT versus Cav1/ exposed to peritoneal dialysis fluid; *P = 0.04 for Cav1/ exposed to pertoneal
dialysis fluid versus Cav1/ exposed to peritoneal dialysis fluid and treated with CI-1040.
C Representative IF of parietal peritoneal sections stained for pan-cytokeratin (green) and FSP-1 (red), and with DAPI to visualize cell nuclei. Scale bar: 30 lm. P = 0.03;
P = 0.01. Arrow shows cytokeratin-FSP-1 double-positive MCs invading the submesothelial stroma.
D Quantification of parietal peritoneal EMT as the number of double-positive pancytokeratin- and FSP-1-stained cells.
E Quantification of CD31-positive cells; *P = 0.038; **P = 0.005.
F Results of a 30-min peritoneum equilibration test performed on the last day of the experiment (see Materials and Methods) to measure total peritoneal volumes.
**P = 0.0023 for WT versus Cav1/ exposed to peritoneal dialysis fluid; **P = 0.0043 for Cav1/ exposed to peritoneal dialysis fluid versus Cav1/ exposed to
peritoneal dialysis fluid and treated with CI-1040.
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impacts on structure and signaling because E-cadherin limits
pathways that lead to EMT induction, such as NF-jB and b-catenin
pathways, and contributes to Snail-1 inhibition (Solanas et al,
2008). This conclusion is supported by our finding that silencing
Cav1 in post-PD HPMCs further increased their invasiveness,
whereas this was significantly reduced upon ectopic Cav1
expression. Interestingly, the fact that Cav1 levels may be increased
by drugs with anti-inflammatory and anti-fibrotic activity, such as
dexamethasone or tamoxifen, amplifies the translational implica-
tions of these findings.
Our study establishes Cav1 as a major checkpoint in the transi-
tion of MCs and ECs from an epithelial toward a mesenchymal
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Figure 9. Cav1 ectopic expression reverses EMT in human peritoneal MCs from PD patients.
A Confocal IF of a-SMA (red) and Cav1 (green) in HPMCs from the peritoneal effluent of patients undergoing PD. Representative image from eight independent
experiments from eight different patients. Scale bar: 50 lm.
B Western blot for E-cadherin, a-SMA, and Cav1 in whole-cell lysates of effluent-derived HPMCs infected with control (L) or Cav1-expressing lentivirus (Cav1). Tubulin
was detected as a loading control. Data are representative of three independent experiments.
C Western blots showing the expression of E-cadherin, phospho-ERK, and Cav1 in whole-cell lysates of effluent-derived HPMCs transfected with control (scr) or Cav1-
targeting siRNAs and treated with 2 lM CI-1040 or DMSO. Tubulin was detected as a loading control. Data are representative of three independent experiments.
D Western blot showing expression of vimentin and Cav1 in effluent-derived HPMCs transfected with Cav1 siRNAs (left) or infected with Cav1 lentivirus (right). Data are
representative of three independent experiments.
E E-cadherin mRNA expression in effluent-derived HPMCs expressing Cav1 siRNAs or lentivirally encoded Cav1. Quantitative RT–PCR was performed on total RNA.
Histone H3 mRNA was used for normalization. Bars represent means  SEM of duplicate determinations in six independent experiments from six patients.
**P = 0.002.
F Snail-1 mRNA expression in effluent-derived HPMCs expressing Cav1 siRNAs or lentivirally encoded Cav1. PCR and normalization as in (E). Bars represent
means  SEM of duplicate determinations in five independent experiments from five patients. **P = 0.008.
G Effect of Cav1 silencing or ectopic expression on invasion by effluent-derived HPMCs. MCs expressing lentivirally encoded Cav1 shRNA (LCav1KD) or Cav1 protein
(LCav1) were allowed to invade for 24 h through type I collagen-coated transwell filters. Invading cells were fixed and nuclei were counted in ten fields per sample
using a fluorescence microscope (40× magnification). Each experiment was performed in duplicate, and six experiments were performed from six patients.
**P = 0.002.
Source data are available online for this figure.
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identity. The control of Cav1 levels in chronic inflammatory fibrotic
pathologies is thus relevant to the understanding of chronic inflam-
mation and also suggests possible therapeutic routes. The molecular
mechanisms underlying EMT and fibrosis in the peritoneum may
also be relevant to clinical issues unrelated to PD, such as the
prevention of post-operative peritoneal adhesions and the control of
peritoneal metastasis.
Materials and Methods
Mice
Cav1-deficient mice (STOCK Cav1tm1Mls/J; Razani et al, 2001a)
and WT B6129SF2/J controls were from The Jackson Laboratory
(USA) and were used for in vivo and ex vivo experiments. Cav1-
deficient mice and WT littermates (B6.Cg-CAV1tm1mls/J; Drab
et al, 2001) were used to confirm ex vivo experiments. Mice from
both genders were equally used in the different experimental condi-
tions. All animal procedures conformed to EU Directive 2010/63EU
and Recommendation 2007/526/EC regarding the protection of
animals used for experimental and other scientific purposes,
enforced in Spanish law under Real Decreto 1201/2005, and were
approved by CNIC animal care and ethics committee.
Cells
Mouse peritoneal MCs were obtained by digestion of parietal perito-
neum samples from WT and Cav1/ mice. The samples were
digested with a 0.125% trypsin solution containing 0.01% EDTA for
15 min with occasional agitation at 37°C. Cells were cultured in
DMEM F12 supplemented with 20% fetal calf serum, 50 U/ml peni-
cillin, 50 lg/ml streptomycin, and 1% Biogro-2 (containing insulin,
transferrin, ethanolamine, and putrescine) (Biological Industries,
Beit Haemek, Israel). Biogro-2 is routinely added to favor in vitro
MC differentiation, being washed out the day before performing the
experiment.
To induce EMT, mouse MCs were treated with TGF-b1 (2 ng/ml)
(R&D Systems, Minneapolis, MN) for the indicated times.
HPMCs were obtained by digestion of omentum samples from
patients who were undergoing unrelated abdominal surgery (Stylia-
nou et al, 1990). The samples were digested with a 0.125% trypsin
solution containing 0.01% EDTA for 15 min with occasional
agitation at 37°C. Cells were cultured in Earle’s 199 medium supple-
mented with 10% fetal calf serum, 50 U/ml penicillin, 50 lg/ml
streptomycin, and 1% Biogro-2. To induce EMT, HPMCs were
treated with TGF-b1 (1 ng/ml) as described previously (Yanez-Mo
et al, 2003) (Aroeira et al, 2005). The cytokine dose used is in the
range of those detected in peritoneal dialysis fluids from patients
with peritonitis (Lai et al, 2000) and is similar to those used in
previous studies (Yang et al, 1999; Yanez-Mo et al, 2003). The
human mesothelial cell line MeT-5A (ATCC, Rockville, MD) was
cultured in Earle’s M199 as above.
Effluent-derived MCs were isolated from clinically stable PD
patients as described previously (Lopez-Cabrera et al, 2006). To
control for fibroblast contamination, the purity of HPMC and
effluent-derived MC cultures was determined from the expression of
the standard mesothelial markers intercellular adhesion molecule
(ICAM)-1 and cytokeratin (Aroeira et al, 2007), (Strippoli et al,
2008, 2012). MCs from PD effluents generally express cytokeratins,
although at low levels. MC cultures are generally negative for the
endothelial marker CD31 and the pan-leukocyte marker CD45.
Omental and peritoneal effluent-derived MCs were generally > 95%
pure by FACS, and samples with > 5% contaminating cells were
discarded. ICAM-1 expression was also used to monitor the purity
of mouse MCs (Supplementary Fig S7). Effluent-derived MCs were
cultured in Earle’s M199 as above.
The study was approved by the ethics committee of the Hospital
Universitario de la Princesa (Madrid, Spain). Written informed
consent was obtained from all PD patients and from omentum
donors prior to elective surgery.
MLECs were obtained and cultured as described (Oblander
et al, 2005). Briefly, lungs from WT or Cav1/ mice were
excised, disaggregated and digested in 0.1% collagenase (GIBCO)
for 1 h at 37°C. The cell suspensions were seeded onto plates
coated with 10 lg/ml fibronectin (Sigma), 10 lg/ml collagen I
(PureCol) and 0.1% gelatin (Sigma). After attachment, cells were
negatively selected with anti-CD16/CD32 mAb (BD Biosciences)
coupled to magnetic beads (Dynal, Invitrogen) and then positively
selected with magnetic-bead-coupled anti-ICAM-2 (BD Biosciences).
Mouse embryonic fibroblasts (MEFs) were obtained from day 13.5
embryos and cultured essentially as described (Razani et al, 2001a).
Antibodies and chemicals
Monoclonal antibodies against Snail-1, ERK1/2, phospho-ERK1/2,
phospho-SMAD1-5-8, and Cav1 were from Cell Signaling Techno-
logy; monoclonal antibodies against E-cadherin, b-catenin, and
c-catenin were from BD (Becton-Dickinson Laboratories, Mountain
View, CA); monoclonal antibodies against occludin was from Invitro-
gen (Carlsbad, CA); monoclonal antibodies against tubulin, a-SMA,
Caveolin-1
ERK pathway
Snail-1
TGF-β1
α-SMA  Type I collagen fibronectin
proteins related to TGF-β1 activation
EMT and FIBROSIS
SMAD1-5
E-cadherin downregulation
SMAD2-3
Figure 10. Control of EMT-related signalling pathways by Cav1.
Cav1 regulates peritoneal EMT and fibrosis through an action on ERK and SMAD
pathways.
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a-catenin, vimentin, pan-cytokeratin, and fibronectin were from
Sigma (Saint Louis, MO); monoclonal anti-N-cadherin and polyclonal
anti-ZO-1 were from Zymed (Invitrogen, Carlsbad, CA); polyclonal
anti-actin, -SMAD2-3, and -phospho-MEK were from Santa Cruz
Biotechnology (CA); and polyclonal anti-phospho SMAD2-3 was
from Biosource (Camarillo, CA). Monoclonal anti-CD54 was from
Biolegend (San Diego, CA); polyclonal anti-Fsp1 was from Dako
(Glostrup, Denmark); monoclonal anti-CD31 from Serotec (Oxford,
UK); and polyclonal anti-Ki67 from Abcam (Cambridge, UK). Mono-
clonal anti-JAM-A clone BV-11 was a gift from Dr. E. Dejana (Milan
Italy). Fluor 647–phalloidin and Hoechst 33342 were from Invitrogen
(Carlsbad, CA). CI 1040 was from Selleck (Houston, TX).
Western blotting
Cells were lysed, and Western blotting was performed as previously
described (Strippoli et al, 2008).
Confocal microscopy and immunofluorescence
Cells were fixed for 20 min in 3% formaldehyde in PBS, permeabi-
lized in 0.2% Triton X-100/PBS for 5 min, and blocked with 2%
BSA for 20 minutes. For E-cadherin staining, cells were fixed and
permeabilized in ice-cold methanol for 5 min. Secondary antibodies
(conjugated to Alexa-647, -488, and -541) were from Pierce Chemi-
cal Company (Rockford, IL, USA). Confocal images were acquired
using a Leica SP5 spectral confocal microscope. The spectral
technology allows discrimination between yellow and green
fluorescence. In some experiments, Leica SP8 confocal microscope
with stimulated emission depletion (STED) microscopy (super-
resolution microscopy) was used.
Flow cytometry
Cells were trypsinized, washed, and resuspended in PBS. Cells
(1 × 105) were incubated with 100 ll monoclonal anti-ICAM-1,
washed with PBS and then incubated with 100 ll of a 1:50 dilution
of FITC-conjugated anti-mouse Ig. Alternatively, 1 × 105 cells were
incubated with 100 ll of a 1:50 dilution of FITC-conjugated monoclo-
nal anti-CD45 for 20 min at 4°C and washed with PBS. Fluorescence
was measured using a FACScan flow cytometer (Becton Dickinson
Labware, Lincoln Park, NJ, USA).
siRNA-mediated Cav1 knockdown and lentiviral infection
MCs (1.2 × 105) were seeded on 24-well plates 24 h prior transfec-
tion. Cells were transfected overnight with 80 pmol of siRNA
corresponding to human Cav1 bases 403–423 (target sequence:
AAGAGCTTCCTGATTGAGATT) or the same amount of control
siRNA in 400 ll antibiotic-free medium containing 1 ll Dharmafect
1 (Dharmacon, Lafayette, CO) (Beardsley et al, 2005). Transfections
were repeated after 48 h. 72 h after the last transfection, knock-
down efficiency was determined by Western blot and cells were
processed as indicated. An alternative Cav1 siRNA was designed
(50-GACGTGGTCAAGATTGACTTT-30) corresponding to human
Cav1 bases 254–277. This sequence was cloned into pLVX-shRNA2,
which contains a ZsGreen1 reporter (Clontech, Mountain View,
CA). Lentiviral infection was performed as in Goetz et al (2011).
MCs were also infected with pRR-CMV-Cav-IRES-GFP with pLVX-
Cav-ZsGreen, or with empty vectors as a control.
Cell transfection and luciferase assays
Smad3 transcriptional activity was measured by transient transfec-
tion of MeT-5A cells with the PAI-1 reporter plasmid (van Zonneveld
et al, 1988) and SMAD1–5–8 activity by transfection with BRE-luc
reporter plasmid (Korchynskyi & ten Dijke, 2002). Cells (2 × 105)
were transfected with 2 lg of reporter plasmid together with 500 ng
of pRL-null, which contains a promoterless Renilla luciferase gene
(Promega, Madison, WI). For transfections, cells were incubated for
4 h with a 1:2.5 w/v (ng/ll) mix of DNA and Lipofectamine
(Lipofectamine 2000; Invitrogen, Carlsbad, CA, USA) in serum-free
medium. Cells were subsequently pretreated overnight with vehicle
(DMSO) or CI-1040 (2 lM) and stimulated with TGF-b1 for 9 h.
Luciferase activity was measured by the dual-luciferase reporter
assay system (Promega) using a Sirius single tube luminometer
(Berthold Detection Systems GmbH, Pforzheim, Germany). All
experiments were performed in triplicate.
Reverse-transcriptase polymerase chain reaction
Total RNA was extracted with the RNeasy kit (Qiagen GmbH,
Hilden, Germany), and cDNA was obtained from 500 ng RNA with
the Omniscript RT kit (Qiagen). Quantitative PCR was carried out in
a LightCycler (Roche Diagnostics GmbH, Mannheim, Germany)
using a SYBR Green kit (Roche Diagnostics GmbH) and the follow-
ing specific primer sets: 50TGAAGGTGACAGAGCCTCTG30 and 50TG
GGTGAATTCGGGCTTGTT30 for E-cadherin; 50GCAAATACTGCAA
CAAGG30 and 50GCACTGGTACTTCTTGACA30 for Snail-1; 50GCTAT
GATGAGAAATCAACCG30 and 50GCTTCCCCATCATCTCCATTC30
for type I collagen; 50CCTGAAGCTGAAGAGACTTGC30 and 50CGT
TTCTCCGACCACATAGGA30 for fibronectin; 50GCGACCCTAAACA
CCTCAAC30 and 50ATGCCGTCAAAACTGTGTGTC30 for Cav1; 50 F
aggaaatggctcgtcaccttcgtgaata30 and 50 ggagtgtcggttgttaagaactagagct30
for vimentin; 50AAAGCCGCTCGCAAGAGTGCG30 and 50-ACTTGCC
TCCTGCAAAGCAC30 for histone H3 (used for normalization);
50CAAGTATCAGGGTCAAGTGCC30 and 50CCAAATCCGATACGTGA
TCTTC30 for mouse E-cadherin; 50AGCTGGCCAGGCTCTCGGTG30
and 50GCAGCCAGACTCTTGGTGCTT30 for mouse Snail-1; 50GCAAA
CCTATAGCTGAGAAGTG30 and 50CAAGTACAGTCCACCATCATC30
for mouse FN; 50CAGTCGCYGTCAGGAACC30 and 50GTGCTGT
CTTCCTCTTCACAC30 for mouse a-SMA; 50TGCCGCGACCTCAA
GATGTG30 and 50CACAAGGGTGCTGTAGGTGA30 for mouse type I
collagen; and 50AAAGCCGCTCGCAAGAGTGCG30 and 50-ACTT
GCCTCCTGCAAAGCAC30 for histone H3. All experiments were
carried out in duplicate. After amplification, PCR products were
confirmed by melting-curve analysis and gel electrophoresis.
Preparation of cell-derived extracellular matrices and
quantitative proteomics analysis
Cell-derived extracellular matrices were prepared as previously
described (Castello-Cros & Cukierman, 2009; Goetz et al, 2011). The
resulting soluble protein extracts from ECM preparations were
digested following the whole-proteome in-gel digestion method
(Bonzon-Kulichenko et al, 2011) using modified porcine trypsin
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(Promega) at a final ratio of 1:20 (trypsin–protein). Digestion
proceeded overnight at 37°C in 100 mM ammonium bicarbonate,
pH 8.8. A total of 200 lg of each peptide mixture were labeled with
different iTRAQ tags according to the manufacturer’s protocol,
desalted, and joined together.
The resulting tryptic peptide mixtures were subjected to nano-
liquid chromatography coupled to mass spectrometry analysis
for protein identification and quantification on a Q-Exactive
mass spectrometer (Thermo Fisher, San Jose´, CA, USA). An
enhanced FT-resolution spectrum (resolution = 70.000) followed
by the MS/MS spectra from most intense fifteen parent ions
were analyzed along the chromatographic run (272 min). See
Field et al (2013) for details. Protein identification from tandem
mass spectra was done using SequestTM running under Proteome
Discoverer 1.4.0.288 (Thermo Fisher Scientific). Sequest results
were analyzed using the probability ratio method (Martinez-
Bartolome et al, 2008) and filtered out using the refined FDR
method (Jorge et al, 2009). Protein quantification from reporter
ion intensities and statistical analysis of quantitative data were
performed using QuiXoT, as described (Jorge et al, 2009; Navarro
et al, 2014).
In vitro permeability assay
The permeability of mouse MC monolayers was measured with the
Millipore In Vitro Permeability Assay kit (Chemicon). Cells
(100,000) were seeded on the membranes of the chambers
provided. After 48 h, dextran-FITC was added to the upper chamber
and was recovered after 40 min from the bottom chamber and
measured in a fluorimeter.
Invasion assays
For 3-dimensional invasion assays, cells (2 × 105) were treated
with CI-1040 (2 lM) or vehicle for 12 h and then seeded in Ibidi
15-well chambers and allowed to attach for 3 h. 40% matrigel
(10 ll) in combination with type I collagen (30 lg/ml) in serum-
free medium was laid over the cells. After 1 h, 50 ll full medium
containing 20% serum was added and cells incubated for 20 h.
Cells were fixed with 3% paraformaldehyde (PFA), permeabilized
with 0.25% Triton PBS, and stained for 12 h with rhodamine-
phalloidin, anti-cytokeratin and Hoechst in PBS. Confocal images
were captured with a Leica SP5 fitted with a 40× oil objective.
Maximum projection images consist of 65 individual images with
a z-distance of 120 lm (n = 8, *P-value < 1 × 10E-5). Alterna-
tively, migration and invasion assays were performed using
polycarbonate inserts with a 8-lm pore size (Costar, Cambridge,
MA). For invasion assays, inserts were precoated with 40 ll type I
collagen (300 lg/ml) (PureCol, Inamed, Fremont, Canada) and
incubated overnight at 37°C to allow gel formation. MCs were
pretreated for 24 h with DMSO or CI-1040 (2 lM) in 10% FBS
M-199 medium. MCs (5 × 104) in 100 ll assay medium (M-199
0% FBS) were added to the upper chamber. Invasion stimulus
(10% FBS) was added to the lower chamber in 600 ll assay
medium. After 24 h, inserts were fixed with 4% PFA, non-invading
cells on the upper face of the membrane were removed with a
cotton swab, filters were cut, and nuclei of invading cells were
stained with Hoechst 33342. Invading cells were counted in ten
fields per sample using a fluorescence microscope (40× magnifica-
tion). Each experiment was carried out in duplicate, and at least 5
experiments were performed.
Whole-mount staining of mesenterium
Live mice anesthesized with a mixture of zoletil-dontor were surgi-
cally opened and perfused with 1% PFA in PBS at 7 ml/min,
using a programmable syringe (Harvard Apparatus). Ventral
mesenterium was collected and post-fixed in 1% PFA for 1 h at
room temperature (RT). Tissues were stained as described in
Baluk et al (2007). Briefly, tissues were incubated overnight (O/N)
at RT with PBS containing 0.3% Triton X-100, 5% goat serum
(Jackson ImmunoResearch) and primary antibody. Samples were
then thoroughly washed with 0.3% Triton X-100 in PBS and
stained with appropriate secondary antibodies O/N at RT. Second-
ary antibody was Alexa488 donkey anti-rat. After final washes,
labeled samples were post-fixed in 1% PFA for 30 min and
mounted for microscopy in Prolong Gold antifade reagent
(Molecular Probes). Confocal z-stacks up to 100 lm in depth were
obtained using a LSM 700 laser-scanning microscope equipped
with a LD LCI Plan/Apochromat 25x/0.8 Imm Korr DIC M27
objective (Zeiss). Images were processed to obtain maximal
projections, fluorescence intensity profiles, and colocalization data
(Imaris, Volocity and ImageJ softwares).
Intravital imaging of paravascular permeability
Ears were taped to the center of a coverslip and attached with
high vacuum grease. Dibutylphtalate (1:1 dissolved in acetone)
was applied topically in both sides of the ear 24 h prior to imag-
ing to induce a cutaneous inflammatory response. Hairless areas
were examined using a HCX PL APO lambda blue 20.0 × 0.70
IMM UV objective (multi-immersion, glycerol) coupled to an
inverted microscope (DMI6000; Leica) equipped with a confocal
laser-scanning unit (TCS-SP5; Leica). Non-invasive intravital imag-
ing procedures were performed in a thermostatic chamber at 37°C.
For short-term studies (1–2 h), animals were first anesthesized
with i.p. ketamine (50 mg/kg), xylazine (10 mg/kg), and acepro-
mazine (1.7 mg/kg), and repeated half-doses were administered
when needed over the course of the experiments. Vessels were
traced with 100 ll 70 kDa TRITC-dextran (Molecular Probes)
dissolved in PBS at concentration 70 lM. Optimal confocal
sections (spaced 0.63 lm along the z-axis) were obtained and
processed using Imaris version 7.3.1 (Bitplane). Mean fluorescence
intensity analysis was performed using LAS AF Software (Leica
Microsystems).
PD fluid exposure in mice
Sixty-four 12- to 16-week-old mice were used (32 WT B6129SF2/J
and 32 Cav1/ Cav1tm1Mls/J). PD fluid or saline solution was
instilled via a peritoneal catheter connected to an implanted subcu-
taneous mini access port under isoflurane (MTC Pharmaceuticals)
anesthesia (Access Technologies, Skokie, IL, USA) (Loureiro et al,
2011). Animals were implanted with the peritoneal access port to
receive 0.2 ml of saline with 1 IU/ml of heparin during the first
week after surgery, to facilitate wound healing. Thereafter, four
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groups of 16 mice (each of them formed by 8 WT and 8 Cav1/
mice, matching gender, weight, and age) were instilled during a
4-week period, 5 days per week as follows: group A received 1.5 ml
standard PD fluid composed of lactate-buffered 4.25% glucose
(StaySafe, Fresenius, Bad Homburg, Germany); group B received
1.5 ml standard PD fluid contemporaneously with oral CI-1040
(200 mg/kg per day); group C received 1.5 ml saline solution; and
group D received saline solution contemporaneously with 200 mg/kg
CI-1040. CI-1040 was administered orally with a syringe and was
dissolved in full-fat milk to promote absorption (Lorusso et al,
2005). Food and water were provided ad libitum during the experi-
ment, and animals were housed in individually ventilated cages, 4
animals/cage. On the final day of treatment, all animals underwent
The paper explained
Problem
Peritoneal dialysis (PD) is an alternative to hemodialysis for the treat-
ment of end-stage renal disease. During PD, the peritoneal membrane
(PM) acts as a permeable barrier across which ultrafiltration and
diffusion take place. The number of patients included in PD programs
has progressively increased worldwide, and is now used by 10–15% of
the global dialysis population. Several studies have confirmed equiva-
lent effectiveness, mortality and fluid balance status compared with
hemodialysis, at least for the first 4–5 years. In addition, PD offers
major advantages in terms of quality of life, cost, and opportunities
for home-based treatment. However, chronic exposure to hyperosmo-
tic, hyperglycemic and acidic dialysis solutions, as well as episodes of
peritonitis and hemoperitoneum, can cause acute and chronic inflam-
mation and injury to the PM, which undergoes progressive EMT (epi-
thelial to mesenchymal transition of the PM mesothelium) and
subsequent fibrosis, as well as angiogenesis and vasculopathy, eventu-
ally leading to discontinuation of PD. There is thus a high clinical
priority in understanding the underlying molecular mechanisms that
cause EMT—the first step towards fibrosis—as well as the identifica-
tion of new potential tools to counteract the onset of peritoneal fibro-
sis is of high clinical relevance.
Results
This study analyzes the role of caveolin-1 (Cav1), a key structural
component of endocytic and mechanoresponsive caveolae, in the
induction of EMT and subsequent peritoneal fibrosis, and the molecu-
lar mechanisms involved. The peritoneum of Cav1/ mice showed
increased EMT, thickness and fibrosis, which was further increased
upon exposure to PD fluids. Lack of Cav1 was associated with hyper-
activation of a MEK-ERK1/2-Snail-1 pathway that regulates the
Smad2-3/Smad1-5-8 balance. Pharmacological blockade of MEK
rescued E-cadherin and ZO-1 localization at inter-cellular junctions,
reduced fibrosis, and restored peritoneal function in Cav1/ mice
exposed to PD fluids. Moreover, PD-patient-derived mesothelial cells
that had already undergone EMT in vivo reacquired epithelial features
upon treatment with drugs increasing Cav1 levels or ectopic expres-
sion of Cav1.
Impact
Our study establishes Cav1 as a major checkpoint in the transition
from an epithelial toward a mesenchymal identity in the peritoneum.
The efficacy of MEK pharmacological inhibitors in counteracting the
EMT/fibrosis developed in Cav1/ mice during PD warrants further
translational studies. Moreover, our studies establish MEK inhibition
as a candidate rationale for therapy of other pathological conditions
not related to PD, such as post-operative adhesions, and other non-
peritoneal fibrotic inflammatory diseases.
a peritoneal equilibrium test. Mice were instilled with 2 ml PD
solution and were anesthetized 30 min later with isoflurane (MTC
Pharmaceuticals, Cambridge, Ontario, Canada) and sacrificed. Total
peritoneal volumes were recovered, and parietal peritoneum
samples were obtained from the side contralateral to the implanted
catheter.
Statistical analysis
Statistical significance was determined with a t-test or the nonpara-
metric Mann–Whitney rank-sum U-test with OriginPro7 software
(OriginLab Co.) or GraphPad Prism version 4.0 (La Jolla, CA, USA).
Differences were considered significant at P < 0.05.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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